Hangover Cure Products Vary Wildly by Country With Zero Clinical Proof

Alcohol hangovers impose real cognitive, psychomotor, and occupational costs, yet the global market for hangover remedies operates almost entirely without clinical evidence. This study from Utrecht University set out to systematically map and compare hangover product markets in three culturally distinct countries — the United Kingdom, Australia, and Japan — using Amazon as a standardized retail window. The researchers hypothesized that country-specific dietary traditions, alcohol preferences, and supplement cultures would be reflected in meaningfully different product formulations.

The methodology was straightforward but rigorous in scope. Amazon was searched using the terms 'hangover treatment' and 'hangover cure' with delivery set to London, Sydney, and Tokyo, yielding 390, 454, and 325 initial hits respectively. After removing duplicates and excluding products unrelated to alcohol hangover or lacking active ingredients (such as cooling eye masks), the final sample comprised 19 UK products, 19 Australian products, and 24 Japanese products — a total of 62 unique products. Ingredient dosages were recorded from product labels and Amazon listings, and compared against national recommended dietary intake (RDI) and upper intake level (UL) thresholds. Japan was excluded from dosage safety analysis because most Japanese products did not disclose ingredient amounts.

The UK market was dominated by electrolyte-heavy formulations: potassium appeared in 63.2% of products, sodium in 57.9%, and vitamin C in 52.6%. B vitamins were also common, with B12 in 47.4% and B1 in 42.1% of products. Natural or botanical ingredients were notably scarce — DHM appeared in none of the 19 UK products, milk thistle in only 10.5%, and beetroot in 15.8%. Powders were the most popular UK dosage form at 42.1%. Several products exceeded RDI thresholds for vitamins C, B6, and B12, and one product exceeded the UL for vitamin C.

Australia showed a broader ingredient profile. Vitamins B1, B6, B12, and sodium each appeared in 47.4% of products, but natural compounds were more prominent than in the UK — dihydromyricetin (DHM) featured in multiple Australian products, reflecting influence from the US market. Capsules (31.6%) and drinks (26.3%) were the preferred dosage forms. Japan's market was the most distinctive: curcumin led at 45.8%, followed by L-ornithine at 29.2%, with vitamin C and B2 each at 20.8%. Tablets dominated at 50.0%. Notably, no single product was marketed in all three countries, underscoring how culturally siloed these markets remain.

Perhaps the most clinically significant finding is the universal absence of rigorous evidence. The authors note that a prior literature review found no double-blind, placebo-controlled human trials supporting any marketed hangover product. This study confirms that situation has not changed. Some ingredients like DHM and curcumin have preclinical or mechanistic rationale, but none have been validated in properly controlled human trials for hangover prevention or reduction. The authors call explicitly for such trials, noting that the current market operates on consumer demand and cultural preference rather than evidence-based medicine.

For clinicians and health-conscious consumers alike, the takeaway is sobering: the hangover supplement market is large, culturally diverse, and entirely unvalidated. Ingredients vary so dramatically between countries that even cross-market comparisons are difficult. Until placebo-controlled trials are conducted, no hangover product can be recommended with confidence, regardless of its ingredient list or country of origin.